TIAA Trust National Association Has $37.14 Million Holdings in Johnson & Johnson (NYSE:JNJ)

TIAA Trust National Association decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 254,087 shares of the company’s stock after selling 14,032 shares during the period. TIAA Trust National Association’s holdings in Johnson & Johnson were worth $37,137,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in JNJ. GUNN & Co INVESTMENT MANAGEMENT INC. grew its position in Johnson & Johnson by 1,194.9% in the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock valued at $37,190,000 after acquiring an additional 218,949 shares during the last quarter. Gilbert & Cook Inc. increased its position in Johnson & Johnson by 3.3% during the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after purchasing an additional 288 shares in the last quarter. Searle & CO. lifted its stake in Johnson & Johnson by 0.3% in the 4th quarter. Searle & CO. now owns 40,462 shares of the company’s stock valued at $6,342,000 after purchasing an additional 126 shares during the last quarter. Buckhead Capital Management LLC boosted its position in Johnson & Johnson by 5.0% in the fourth quarter. Buckhead Capital Management LLC now owns 46,182 shares of the company’s stock valued at $7,239,000 after buying an additional 2,183 shares in the last quarter. Finally, Great Valley Advisor Group Inc. grew its stake in shares of Johnson & Johnson by 8.2% during the fourth quarter. Great Valley Advisor Group Inc. now owns 100,970 shares of the company’s stock worth $15,827,000 after buying an additional 7,613 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $167.16 on Wednesday. The company has a market cap of $402.30 billion, a price-to-earnings ratio of 10.42, a PEG ratio of 2.73 and a beta of 0.52. The company’s fifty day moving average price is $156.42 and its two-hundred day moving average price is $153.60. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $167.81. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.80 EPS. On average, analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JNJ shares. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Finally, Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.